Arcadia Biosciences Announces First-Quarter 2020 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Arcadia Biosciences (RKDA) Tops Q1 EPS by 83c, Revenues Miss; Reiterates FY20 Revenue Guidance Above Consensus
May 13, 2020 4:16 PM EDTArcadia Biosciences (NASDAQ: RKDA) reported Q1 EPS of $0.29, $0.83 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $309 thousand versus the consensus estimate of $800 thousand.
"This is an extraordinary moment in time for all of us," said Matt Plavan, Arcadia's president and chief executive officer. "Our priorities throughout this challenging time remain the same: to maintain the health and safety of... More
